Table 20 Top 10 pairs of drugs with their correlation with subtype 8 of breast cancer, considering both combined and individually
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
Emaxanib | Isradipine | − 0.71 | − 0.60 | − 0.42 | 1 | 1 | 34 |
Semaxanib | Goserelin-Acetate | − 0.68 | − 0.60 | − 0.55 | 2 | 1 | 3 |
Goserelin-Acetate | Formoterol | − 0.68 | − 0.55 | − 0.43 | 3 | 3 | 31 |
Goserelin-Acetate | Camptothecin | − 0.66 | − 0.55 | − 0.38 | 4 | 3 | 72 |
Deferiprone | Racecadotril | − 0.66 | − 0.49 | − 0.40 | 5 | 6 | 56 |
Deferiprone | Etofylline-Clofibrate | − 0.65 | − 0.49 | − 0.47 | 6 | 6 | 15 |
Semaxanib | Raloxifene | − 0.65 | − 0.60 | − 0.54 | 7 | 1 | 4 |
Lidocaine | Romidepsin | − 0.64 | − 0.46 | − 0.41 | 8 | 17 | 49 |
Goserelin-Acetate | Telatinib | − 0.64 | − 0.55 | − 0.41 | 9 | 3 | 44 |
Isradipine | Telatinib | − 0.64 | − 0.42 | − 0.41 | 10 | 34 | 44 |